Skip to main navigation
  • Skip to main content
  • Skip to primary sidebar
Imara

Investor Relations

  • Who We Are
    • Management
    • Board of Directors
  • Investors
    • Press Releases
    • Events and Presentations
    • Stock Information
      • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Contact IR
    • Email Alerts
  • Contact Us

Press Release Details

Breadcrumb

Investors » Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022 at 7:00 AM EST
PDF Version

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m. ET. 

A replay of the webcast will be archived on the “Events and Presentations” section of Imara’s website. 

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Imara is advancing tovinontrine (IMR-687), a highly selective, potent small molecule inhibitor of PDE9 that is an oral, potentially disease-modifying treatment in Phase 2b clinical trials for sickle cell disease and beta-thalassemia. Imara expects to initiate a Phase 2 clinical trial of tovinontrine in heart failure with preserved ejection fraction (HFpEF) in the second quarter of 2022. Imara is also advancing IMR-261, an oral activator of nuclear factor erythroid 2–related factor 2, or Nrf2. For more information, please visit www.imaratx.com.

Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
marin@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com


Primary Sidebar

Contact Us

Footer Social Link

Imara, Inc.
116 Huntington Ave.
6th Floor
Boston, MA 02116
T: 617-206-2020
E: info@imaratx.com

Privacy Policy
Terms of Use
© 2023 Imara, Inc.